JuliaAChapmanMD

Obstetrics & Gynecology • Overland Park, KS

Gynecologic Oncology, Urogynecology & Pelvic Reconstructive Surgery

Associate Professor, Obstetrics and Gynecology, University Kansas School of Medicine

Join to view full profile

Dr. Chapman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chapman's full profile

Already have an account?

Office
10600 Quivira Rd
Ste 130
Overland Park, KS 66215
Phone+1 913-541-5550

Fax+1 913-541-5528

Education & Training

University of California (Irvine)Residency, Obstetrics and Gynecology, 1991 - 1994
University of California (Irvine)Fellowship, Female Pelvic Medicine And Reconstructive Surgery (Obgyn), 1994
Union Memorial HospitalFellowship, Gynecologic Oncology, 1990
University of California (Irvine)Residency, Obstetrics and Gynecology, 1985 - 1989
University of California, Irvine, School of MedicineClass of 1985

Certifications & Licensure

NM State Medical License 2024 - 2027
CA State Medical License 1987 - 2026
MT State Medical License 2024 - 2026
IN State Medical License 2024 - 2025
KS State Medical License 1994 - 2025
MO State Medical License 1994 - 2025
MD State Medical License 1989 - 1990
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com
Fellow (FACOG) American Congress of Obstetricians and Gynecologists

Clinical Trials

Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers Start of enrollment: 2008 Jul 01
Completed
Phase 1
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
Recruiting
Phase 3
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Start of enrollment: 2010 Aug 01
Completed
Phase 2
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Start of enrollment: 2012 Jan 09
Completed
Phase 3
Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection Start of enrollment: 2012 Jan 03
Active, not recruiting
Join now to see all

Publications & Presentations

PubMed

314 citations
High-Dose Parenteral Ascorbate Enhanced Chemosensitivity of Ovarian Cancer and Reduced Toxicity of Chemotherapy
Yan Ma, Julia Chapman, Mark Levine, Kishore Polireddy, Jeanne Drisko
Science Translational Medicine. 2014-02-05
9 citations
Disparities in ovarian cancer survival at the only NCI-designated cancer center in Kansas.
Shariska Petersen, Parmida Shahiri, Andrea Jewell, Lori Spoozak, Julia Chapman
American Journal of Surgery. 2021-04-01
29 citations
Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial.
Jung-Min Lee, Richard G Moore, Sharad Ghamande, Min S Park, John P Diaz
Clinical Cancer Research. 2022-10-03

Press Mentions

Benefits of High-Dose Vitamin C for Ovarian Cancer PatientsFebruary 6th, 2014

Professional Memberships

American College of Obstetricians and Gynecologists
Fellow